The University of Southampton
University of Southampton Institutional Repository

Gene expression profiling in an open-label randomised phase 3 trial (REMoDL-B) of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma

Gene expression profiling in an open-label randomised phase 3 trial (REMoDL-B) of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma
Gene expression profiling in an open-label randomised phase 3 trial (REMoDL-B) of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma
Background: Biologically distinct sub-types of diffuse large B-cell lymphoma (DLBCL) can be identified using gene expression analysis to determine their cell of origin (COO), corresponding to germinal centre (GCB) or activated B‐cells (ABC). This study investigated whether adding bortezomib(B) to standard therapy could improve outcomes in these subtypes.

Methods: The REMoDL-B trial is an open-label adaptive two-stage randomised controlled trial at 107 centres in the United Kingdom and Switzerland. Eligible patients (pts) had previously untreated, histologically confirmed DLBCL with sufficient diagnostic material for gene expression profiling and pathology review; age 18 years or older; Eastern Cooperative Oncology Group performance status of ≤2; bulky stage I or stage II-IV requiring full course chemotherapy; measurable disease, and cardiac, lung, renal and liver function sufficient to tolerate chemotherapy. Pts initially received 1 cycle of standard R‐CHOP. During this time, gene expression profiling by whole genome cDNA-mediated annealing, selection, extension and ligation assay was performed on routine diagnostic biopsy material. Patients were then centrally assigned (1:1) via a web-based system, with block randomisation stratified by international prognostic index and COO subtype to continue R‐CHOP +/‐ bortezomib (1.3 mg/m2 IV or 1.6 mg/m2 SC) days 1+8 for cycles 2‐6. The primary endpoint was 30 month progression‐free survival (PFS) for the GCB + ABC population. The primary analysis was intention-to-treat. The safety population consisted of all participants who received at least one dose of study drug. The study was registered at ClinicalTrials.gov: NCT01324596. We report the PFS and safety outcomes for patients in the follow-up phase after the required number of events occurred. Recruitment and treatment has completed for all participants, with long-term follow-up continuing

Findings: Between June 2011 and June 2015, 1128 eligible pts were registered and a total of 918 randomised. There was no evidence for a difference in PFS in the combined GCB + ABC population between R‐CHOP (N=361)and RB‐CHOP (N=358) (30 month PFS: 70.6% vs 75.2% respectively) adjusted HR = 0.82, 95% CI 0.63 - 1.08; P=0.16. The most common Grade ≥3 adverse event experienced was haematological toxicity, with 178 (39.8%) and 187 (42.1%) of pts receiving R-CHOP and RB-CHOP experienced, respectively. However, RB‐CHOP was not associated with increased haematological toxicity and 87% of pts completed 6 cycles; Grade ≥3 neuropathy occurred in 3.8% RB‐CHOP vs 1.8% R‐CHOP pts. Serious adverse events occurred in 190 (42.5%) and 223 (50.2%) of pts, including 5 and 4 treatment-related deaths in pts receiving R-CHOP and RB-CHOP, respectively.

Interpretation: This is the first large-scale study in DLBCL to use real-time molecular characterisation for prospective stratification and randomisation, and subsequent analysis of biologically distinct subgroups. The addition of bortezomib did not improve outcomes in the ABC subgroup as expected, but proteosome inhibition could be investigated as a possible means to improve the treatment of cytogenetic 'double-hit' DLBCL.

Funding: Janssen-Cilag, Bloodwise and Cancer Research UK.
1474-5488
649-662
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Cummin, Thomas
fcce88a2-7ed7-4bde-a5f5-3f3c834382a4
Barrans, Sharon
7d889401-dfa1-4651-9037-b63d23eea79f
Maishman, Tom
cf4259a4-0eef-4975-9c9d-a2c3d594f989
Mamot, Christoph
40d9310f-6633-4051-b0e8-50cd681cee29
Novak, Urban
17fe7a01-bfad-4cb7-b5cf-149c70f234e5
Caddy, Joshua
c9f48059-2d70-45e4-a80a-978bf74fac34
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Kazmi-Stokes, Shamim
db8b1a87-400b-4628-a9a2-a8e1f64fbef4
McMillan, Andrew
9510fdd5-e37d-4143-b284-e4cae7e4ff14
Fields, Paul
e2472cdc-fe55-42b9-8021-b323185cc086
Pocock, Christopher
a4f62314-9227-43d7-a51d-ff60fc6d7c62
Collins, Graham
450338cb-2bb0-4cef-90a7-7bcd47a12e2f
Stephens, Richard
fd5906e4-8b8e-465c-b5c2-55e1f884492f
Cucco, Francesco
4592e677-378e-40cf-81bb-1c9a3dfc16df
Clipson, Alexandra
4ca214f4-85ea-40b2-85bb-d0931ccc44ae
Sha, Chulin
26db1360-a628-47b4-8b53-e4d5b07eaf31
Tooze, Reuben
e82e0595-1ca2-4886-8f86-af9af62c4ed0
Care, Matthew A.
0d67bad1-ec39-476d-bac6-59ec0e30a9ab
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Du, Ming-Qing
9ccc301c-0d67-41d3-a373-a1485af6dca0
Westhead, David
bc6919e6-e96e-47d6-9a4c-5e3e43ad4a8b
Burton, Catherine
c495cd04-33e5-475b-887d-56689a582e6c
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Cummin, Thomas
fcce88a2-7ed7-4bde-a5f5-3f3c834382a4
Barrans, Sharon
7d889401-dfa1-4651-9037-b63d23eea79f
Maishman, Tom
cf4259a4-0eef-4975-9c9d-a2c3d594f989
Mamot, Christoph
40d9310f-6633-4051-b0e8-50cd681cee29
Novak, Urban
17fe7a01-bfad-4cb7-b5cf-149c70f234e5
Caddy, Joshua
c9f48059-2d70-45e4-a80a-978bf74fac34
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Kazmi-Stokes, Shamim
db8b1a87-400b-4628-a9a2-a8e1f64fbef4
McMillan, Andrew
9510fdd5-e37d-4143-b284-e4cae7e4ff14
Fields, Paul
e2472cdc-fe55-42b9-8021-b323185cc086
Pocock, Christopher
a4f62314-9227-43d7-a51d-ff60fc6d7c62
Collins, Graham
450338cb-2bb0-4cef-90a7-7bcd47a12e2f
Stephens, Richard
fd5906e4-8b8e-465c-b5c2-55e1f884492f
Cucco, Francesco
4592e677-378e-40cf-81bb-1c9a3dfc16df
Clipson, Alexandra
4ca214f4-85ea-40b2-85bb-d0931ccc44ae
Sha, Chulin
26db1360-a628-47b4-8b53-e4d5b07eaf31
Tooze, Reuben
e82e0595-1ca2-4886-8f86-af9af62c4ed0
Care, Matthew A.
0d67bad1-ec39-476d-bac6-59ec0e30a9ab
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Du, Ming-Qing
9ccc301c-0d67-41d3-a373-a1485af6dca0
Westhead, David
bc6919e6-e96e-47d6-9a4c-5e3e43ad4a8b
Burton, Catherine
c495cd04-33e5-475b-887d-56689a582e6c
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f

Davies, Andrew, Cummin, Thomas, Barrans, Sharon, Maishman, Tom, Mamot, Christoph, Novak, Urban, Caddy, Joshua, Stanton, Louise, Kazmi-Stokes, Shamim, McMillan, Andrew, Fields, Paul, Pocock, Christopher, Collins, Graham, Stephens, Richard, Cucco, Francesco, Clipson, Alexandra, Sha, Chulin, Tooze, Reuben, Care, Matthew A., Griffiths, Gareth, Du, Ming-Qing, Westhead, David, Burton, Catherine and Johnson, Peter (2019) Gene expression profiling in an open-label randomised phase 3 trial (REMoDL-B) of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma. Lancet Oncology, 20 (5), 649-662. (doi:10.1016/S1470-2045(18)30935-5).

Record type: Article

Abstract

Background: Biologically distinct sub-types of diffuse large B-cell lymphoma (DLBCL) can be identified using gene expression analysis to determine their cell of origin (COO), corresponding to germinal centre (GCB) or activated B‐cells (ABC). This study investigated whether adding bortezomib(B) to standard therapy could improve outcomes in these subtypes.

Methods: The REMoDL-B trial is an open-label adaptive two-stage randomised controlled trial at 107 centres in the United Kingdom and Switzerland. Eligible patients (pts) had previously untreated, histologically confirmed DLBCL with sufficient diagnostic material for gene expression profiling and pathology review; age 18 years or older; Eastern Cooperative Oncology Group performance status of ≤2; bulky stage I or stage II-IV requiring full course chemotherapy; measurable disease, and cardiac, lung, renal and liver function sufficient to tolerate chemotherapy. Pts initially received 1 cycle of standard R‐CHOP. During this time, gene expression profiling by whole genome cDNA-mediated annealing, selection, extension and ligation assay was performed on routine diagnostic biopsy material. Patients were then centrally assigned (1:1) via a web-based system, with block randomisation stratified by international prognostic index and COO subtype to continue R‐CHOP +/‐ bortezomib (1.3 mg/m2 IV or 1.6 mg/m2 SC) days 1+8 for cycles 2‐6. The primary endpoint was 30 month progression‐free survival (PFS) for the GCB + ABC population. The primary analysis was intention-to-treat. The safety population consisted of all participants who received at least one dose of study drug. The study was registered at ClinicalTrials.gov: NCT01324596. We report the PFS and safety outcomes for patients in the follow-up phase after the required number of events occurred. Recruitment and treatment has completed for all participants, with long-term follow-up continuing

Findings: Between June 2011 and June 2015, 1128 eligible pts were registered and a total of 918 randomised. There was no evidence for a difference in PFS in the combined GCB + ABC population between R‐CHOP (N=361)and RB‐CHOP (N=358) (30 month PFS: 70.6% vs 75.2% respectively) adjusted HR = 0.82, 95% CI 0.63 - 1.08; P=0.16. The most common Grade ≥3 adverse event experienced was haematological toxicity, with 178 (39.8%) and 187 (42.1%) of pts receiving R-CHOP and RB-CHOP experienced, respectively. However, RB‐CHOP was not associated with increased haematological toxicity and 87% of pts completed 6 cycles; Grade ≥3 neuropathy occurred in 3.8% RB‐CHOP vs 1.8% R‐CHOP pts. Serious adverse events occurred in 190 (42.5%) and 223 (50.2%) of pts, including 5 and 4 treatment-related deaths in pts receiving R-CHOP and RB-CHOP, respectively.

Interpretation: This is the first large-scale study in DLBCL to use real-time molecular characterisation for prospective stratification and randomisation, and subsequent analysis of biologically distinct subgroups. The addition of bortezomib did not improve outcomes in the ABC subgroup as expected, but proteosome inhibition could be investigated as a possible means to improve the treatment of cytogenetic 'double-hit' DLBCL.

Funding: Janssen-Cilag, Bloodwise and Cancer Research UK.

Text
REMoDL_B.v6.0_22.11.18.Clean_TM - Accepted Manuscript
Download (999kB)
Text
PIIS1470204518309355 - Proof
Available under License Creative Commons Attribution.
Download (463kB)
Text
FW_ Your submission to The Lancet Oncology_ THELANCETONCOLOGY-D-18-01376R4
Restricted to Repository staff only
Request a copy
Text
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B) an open-label, randomised, phase 3 trial
Restricted to Repository staff only
Request a copy

More information

Accepted/In Press date: 7 December 2018
e-pub ahead of print date: 1 April 2019
Published date: May 2019

Identifiers

Local EPrints ID: 426855
URI: https://eprints.soton.ac.uk/id/eprint/426855
ISSN: 1474-5488
PURE UUID: 1182a9e8-392e-4d5a-85fd-2c72d2c2bbd8
ORCID for Louise Stanton: ORCID iD orcid.org/0000-0001-8181-840X
ORCID for Gareth Griffiths: ORCID iD orcid.org/0000-0002-9579-8021
ORCID for Peter Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 14 Dec 2018 17:30
Last modified: 15 Aug 2019 04:02

Export record

Altmetrics

Contributors

Author: Andrew Davies
Author: Thomas Cummin
Author: Sharon Barrans
Author: Tom Maishman
Author: Christoph Mamot
Author: Urban Novak
Author: Joshua Caddy
Author: Louise Stanton ORCID iD
Author: Shamim Kazmi-Stokes
Author: Andrew McMillan
Author: Paul Fields
Author: Christopher Pocock
Author: Graham Collins
Author: Richard Stephens
Author: Francesco Cucco
Author: Alexandra Clipson
Author: Chulin Sha
Author: Reuben Tooze
Author: Matthew A. Care
Author: Ming-Qing Du
Author: David Westhead
Author: Catherine Burton
Author: Peter Johnson ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×